4.8 Review

Peptides in cancer nanomedicine: Drug carriers, targeting ligands and protease substrates

Journal

JOURNAL OF CONTROLLED RELEASE
Volume 159, Issue 1, Pages 2-13

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2011.10.023

Keywords

Peptides; Cancer; Nanomedicine; Drug delivery; Tumor targeting; Protease-responsive

Funding

  1. National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH)

Ask authors/readers for more resources

Peptides are attracting increasing attention as therapeutic agents, as the technologies for peptide development and manufacture continue to mature. Concurrently, with booming research in nanotechnology for biomedical applications, peptides have been studied as an important class of components in nanomedicine, and they have been used either alone or in combination with nanomaterials of every reported composition. Peptides possess many advantages, such as smallness, ease of synthesis and modification, and good biocompatibility. Their functions in cancer nanomedicine, discussed in this review, include serving as drug carriers, as targeting ligands, and as protease-responsive substrates for drug delivery. Published by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available